Treatment of chronic tinea pedis (athlete's foot type) with topical terbinafine.
Twenty-seven patients with chronic tinea pedis, athlete's foot type, were enrolled in a randomized, double-blind trial of topical treatment with terbinafine 1% cream versus its vehicle (placebo). Patients were examined weekly during 4 weeks of twice-daily treatment and at follow-up 2 weeks after the conclusion of therapy. No adverse events were reported in either treatment group. Drug efficacy was evaluated in 22 patients, of whom nine (41%) were treated with terbinafine and 13 (59%) with placebo. Analysis of combined mycologic and clinical results showed that terbinafine was significantly more effective than placebo at the end of therapy (78% vs zero) and at the 2-week follow-up (89% vs zero) (p less than or equal to 0.001 at both intervals.
Savin
R C
RC
Department of Dermatology, Yale University School of Medicine, CT.
D000279:Administration, Cutaneous; D000328:Adult; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002908:Chronic Disease; D004311:Double-Blind Method; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000008:administration & dosage / Q000627:therapeutic use*; D010105:Oxygenases / Q000037:antagonists & inhibitors*; D010919:Placebos; D011897:Random Allocation; D012074:Remission Induction; D000077291:Terbinafine; D013997:Time Factors; D014008:Tinea Pedis / Q000188:drug therapy*
D000935:Antifungal Agents; D009281:Naphthalenes; D010919:Placebos; D010105:Oxygenases; D000077291:Terbinafine